TY - JOUR
T1 - PARP1 in carcinomas and PARP1 inhibitors as antineoplastic drugs
AU - Wang, Luyao
AU - LIANG, Chao
AU - LI, Fangfei
AU - GUAN, Daogang
AU - Wu, Xiaoqiu
AU - Fu, Xuekun
AU - LYU, Aiping
AU - ZHANG, Ge
N1 - Funding Information:
Acknowledgments: We thank the other academic staff members in Aiping Lu and Ge Zhang’s group at Hong Kong Baptist University. This review was supported by the Natural Science Foundation Council of China (81703049 to F.L.) and the Science and Technology Innovation Commission of Shenzhen Municipality Funds (JCYJ20170307161659648 to F.L.).
PY - 2017/10
Y1 - 2017/10
N2 - Poly (ADP-ribose) polymerase 1 (PARP1), the best-studied isoform of the nuclear enzyme PARP family, plays a pivotal role in cellular biological processes, such as DNA repair, gene transcription, and so on. PARP1 has been found to be overexpressed in various carcinomas. These all indicate the clinical potential of PARP1 as a therapeutic target of human malignancies. Additionally, multiple preclinical research studies and clinical trials demonstrate that inhibition of PARP1 can repress tumor growth and metastasis. Up until now, PARP1 inhibitors are clinically used not only for monotherapy to suppress various tumors, but also for adjuvant therapy, to maintain or enhance therapeutic effects of mature antineoplastic drugs, as well as protect patients from chemotherapy and surgery-induced injury. To supply a framework for understanding recent research progress of PARP1 in carcinomas, we review the structure, expression, functions, and mechanisms of PARP1, and summarize the clinically mature PARP1-related anticancer agents, to provide some ideas for the development of other promising PARP1 inhibitors in antineoplastic therapy.
AB - Poly (ADP-ribose) polymerase 1 (PARP1), the best-studied isoform of the nuclear enzyme PARP family, plays a pivotal role in cellular biological processes, such as DNA repair, gene transcription, and so on. PARP1 has been found to be overexpressed in various carcinomas. These all indicate the clinical potential of PARP1 as a therapeutic target of human malignancies. Additionally, multiple preclinical research studies and clinical trials demonstrate that inhibition of PARP1 can repress tumor growth and metastasis. Up until now, PARP1 inhibitors are clinically used not only for monotherapy to suppress various tumors, but also for adjuvant therapy, to maintain or enhance therapeutic effects of mature antineoplastic drugs, as well as protect patients from chemotherapy and surgery-induced injury. To supply a framework for understanding recent research progress of PARP1 in carcinomas, we review the structure, expression, functions, and mechanisms of PARP1, and summarize the clinically mature PARP1-related anticancer agents, to provide some ideas for the development of other promising PARP1 inhibitors in antineoplastic therapy.
KW - Carcinomas
KW - PARP1
KW - PARP1 inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85031096895&partnerID=8YFLogxK
U2 - 10.3390/ijms18102111
DO - 10.3390/ijms18102111
M3 - Review article
C2 - 28991194
AN - SCOPUS:85031096895
SN - 1661-6596
VL - 18
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 10
M1 - 2111
ER -
